Biodefense Market Size to grow by USD -7161.34 million between 2024-2028
According to a research report “ Biodefense Market” by Type (Vaccines, Drugs ) Application (COVID 19, Anthrax, Smallpox, Botulism, Others ) Geography (Asia, North America, Europe, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD -7161.34 million, at a CAGR of over -4.96% during the forecast period. The global business environment has witnessed a significant increase in the incidence and impact of infectious diseases, pandemics, and bioterrorism events in recent years. Notable instances include the Ebola virus outbreak in West Africa, the Zika virus epidemic in the Americas, and the COVID-19 pandemic in 2020. These events have underscored the vulnerability of populations to biological threats and highlighted the importance of robust biodefense measures. In response, governments, healthcare organizations, and the public have heightened their awareness and efforts to enhance preparedness and response capabilities. However, the threat landscape continues to evolve, with emerging infectious agents, drug-resistant pathogens, and the potential for engineered bioweapons posing new challenges for businesses and industries. These factors underscore the critical need for ongoing investment in biodefense technologies, research, and preparedness strategies to mitigate the risks and protect against potential biological threats.
Browse market data tables, figures, and in-depth TOC on “Biodefense Market” by Type (Vaccines, Drugs ) Application (COVID 19, Anthrax, Smallpox, Botulism, Others ) Geography (Asia, North America, Europe, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Type, the Vaccines segment is projected to dominate the market size in 2024
The global biodefense market has experienced substantial growth in the last two decades due to the increasing threat of viral epidemics and pandemics, most notably the COVID-19 pandemic. This crisis underscores the critical role of biodefense companies in developing innovative countermeasures to manage and mitigate the spread of infectious diseases. Vaccines, such as the rVSV-ZEBOV vaccine for Ebola virus and those for plague, are essential tools in preventing the outbreak and saving lives. The success of these vaccines during various outbreaks highlights the importance of continued investment in biodefense research and development.
By Application, COVID 19 segment is expected to hold the largest market size for the year 2024
In the realm of biosecurity, biodefense vaccines assume pivotal importance, safeguarding against deliberate biological attacks, emerging infectious diseases, and bioterrorism incidents. These vaccines are meticulously engineered to impede the propagation of pathogens that could be employed in hostile acts or emerge naturally. A prime example is the Anthrax Vaccine Adsorbed (AVA), developed by Emergent BioSolutions. This vaccine is a cornerstone in the defense against anthrax, a bacterial agent with potential for weaponization. AVA, licensed in the US and other countries, is stockpiled for emergency use, underscoring its significance in national preparedness and response strategies.
Asia is forecasted to hold the largest market size by region in 2024
The Asian region is experiencing significant growth in the biodefense market, making it the fastest-growing sector globally. This expansion is primarily attributed to the presence of burgeoning economies, such as India and China, within the region. Simultaneously, the persistent issue of terrorism, coupled with the emerging threat of bioterrorism, poses a significant concern for numerous Asian countries. The potential for bioterrorism attacks, given the region's large population, could lead to catastrophic consequences. As a result, the biodefense market in Asia is poised for substantial expansion during the forecast period, driven by the imperative need to safeguard against these threats.
The Biodefense Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The biodefense market encompasses the development, production, and implementation of measures to protect against biological threats, including biological weapons such as viruses, bacteria, chemical agents, and radioactive agents. These threats can cause significant harm to human health and national security, making biodefense a critical area of focus. Biological agents include infectious agents like viruses and bacteria, such as anthrax, botulism, and smallpox, as well as biological toxins produced by organisms like botulinum and ricin. Biotechnology and genetic engineering have advanced our ability to understand and counter these threats, but they also pose new challenges in terms of biosecurity. Military measures, such as stockpiling vaccines and antidotes, and developing protective equipment and decontamination technologies, are essential components of biodefense. Medical measures, including the development of effective treatments and diagnostics, are also crucial. Companies like Emergent Bioscience are at the forefront of the biodefense market, providing solutions for the detection, diagnosis, and response to biological threats. For example, they produce anthrax vaccines and have developed a rapid anthrax diagnostic test using anthrax spores. The biodefense market is expected to grow significantly in the coming years as the threat of biological weapons continues to evolve.
Market Research Overview
The biodefense market encompasses a range of medical countermeasures designed to protect against biothreats, including technologically sophisticated products for detecting, preventing, and treating pandemic flu, bioterrorism agents, and other hazardous biological agents. Biodefense initiatives aim to mitigate the risks posed by intentional and naturally occurring biothreats, such as anthrax spores, smallpox, Ebola virus, Zika virus, botulism toxins, and various viruses, bacteria, fungi, and toxins. Key components of biodefense systems include identifiers, reagents, samplers, detectors/triggering devices, and vaccines. Novel vaccination technologies, such as plasmid DNA constructions and hyperimmune development programs, are crucial for producing effective vaccines against Tier-1 biological agents like anthrax, smallpox, and Ebola. Biodefense efforts also focus on developing drugs, forensics, and nanotechnology to address chemical and nuclear agent threats. Biothreat detection tools, such as gene chips and clinical trials, play a vital role in early detection and diagnosis of infections. Emergent BioSolutions, a leading biodefense company, focuses on developing and manufacturing vaccines and therapeutics for infectious diseases, biological warfare agents, and chemical and nuclear threats. The global biodefense market is expected to grow significantly due to the increasing threat of bioterrorism, economic loss from bio-incidents, and supportive government initiatives like the Anthrax Bioterrorism Preparedness and Response Reauthorization Act. Biodefense strategies involve both military and medical measures, including the development of sophisticated biodefense systems, disease surveillance missions, and preventative steps like stockpiling vaccines and other medical countermeasures. The biodefense market is a critical area of biomedical innovation, addressing the challenges of biological threats to human health and the healthcare infrastructure.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
